Comparing Effectiveness Rituximab (Mabthera®) to Other Second-line Biologics for Rheumatoid Arthritis Treatment in Patients Refractory to or Intolerant of First-line Anti-tumor Necrosis Factor Agent: An Observational Study

Yong-Wook Park, Sang‐Heon Lee, Hyung-In Yang et al.|Journal of Rheumatic Diseases|2017

Cited by 3